42 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
24909677	19	Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.	Glaxosmithkline
24090135	201	Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.	Sanofi
23437772	35	Colloidal aggregation causes inhibition of G protein-coupled receptors.	University of North Carolina At Chapel Hill
20627722	89	Identification of a sulfonamide series of CCR2 antagonists.	Glaxosmithkline
22546204	9	Recent developments and biological activities of thiazolidinone derivatives: a review.	Dr. Hari Singh Gour University
23079519	86	In vivo activity of an azole series of CCR2 antagonists.	Glaxosmithkline
22931505	69	Chemokine receptor antagonists.	National Heart and Lung Institute
22437117	47	Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.	Glaxosmithkline
22047688	51	CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.	Glaxosmithkline
21341682	37	Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.	Telik
20297846	33	Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.	Genzyme
19674898	31	Spiropiperidine CCR5 antagonists.	Roche Palo Alto
20099827	34	Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice.	Chinese Academy of Medical Sciences and Peking Union Medical College
19081254	33	Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.	Astellas Pharma
19014885	32	Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.	Roche Palo Alto
18694645	25	Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.	Astellas Pharma
18539035	20	Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines.	Astellas Pharma
17395464	38	Small molecule antagonists of the CC chemokine receptor 4 (CCR4).	Millennium Pharmaceuticals
17098428	21	Core exploration in optimization of chemokine receptor CCR4 antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute
16698264	37	Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.	Merck Research Laboratories
16539392	29	Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.	Takeda Pharmaceutical
16497499	36	Optimization of 2-aminothiazole derivatives as CCR4 antagonists.	Amgen
16236499	17	Optimization of CCR4 antagonists: side-chain exploration.	Bristol-Myers Squibb Pharmaceutical Research Institute
15863339	29	Identification of chemokine receptor CCR4 antagonist.	Bristol-Myers Squibb Pharmaceutical Research Institute
15026036	91	Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.	Array Biopharma
11720852	51	Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.	Merck Research Laboratories
11720851	52	Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.	Merck Research Laboratories
32667798	66	Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.	Rapt Therapeutics
11311066	76	Design, synthesis, and discovery of a novel CCR1 antagonist.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
11206474	51	Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.	Merck Research Laboratories
10821717	29	Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.	Takeda Chemical Industries
31259550	57	Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T	Rapt Therapeutics
26991939	31	2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.	Glaxosmithkline Medicines Research Centre
23409871	48	Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.	Glaxosmithkline
28947948	62	Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.	Astrazeneca
28801066	33	Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.	Glaxosmithkline
29406702	128	Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.	Gsk Pharmaceuticals R & D
16950396	13	Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.	Osaka University of Pharmaceutical Sciences